Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea
By Elana Gotkine HealthDay Reporter
FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among patients with moderate-to-severe obstructive sleep apnea (OSA) and obesity, according to a study published online June 21 in the Journal of the American College of Cardiology.
Ali Aminian, M.D., from the Bariatric and Metabolic Institute at the Cleveland Clinic, and colleagues examined the long-term relationship between metabolic surgery and incident MACE in patients with OSA and obesity (body mass index, 35 to 70 kg/m2). Patients who underwent metabolic surgery were matched with a nonsurgical control group using overlap weighting methods. Data were included for 970 patients in the metabolic surgery group and 12,687 in the nonsurgical group, with median follow-up of 5.3 years.
The researchers found that the mean between-group difference in body weight at 10 years was 26.6 kg (19.3 percent). The 10-year cumulative incidence of MACE was 27.0 and 35.6 percent in the metabolic surgery and nonsurgical groups, respectively (adjusted hazard ratio, 0.58). The 10-year cumulative incidence of all-cause mortality was 9.1 and 12.5 percent in the metabolic surgery and nonsurgical groups, respectively (adjusted hazard ratio, 0.63).
"In select patients, bariatric surgery is a lifesaving treatment," Aminian said in a statement. "The MOSAIC study suggests the presence of a dose-dependent response between the amount of weight loss and cardiovascular benefits in patients with obstructive sleep apnea; the greater the weight loss, the lower the risk of heart complications."
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Exercise + GLP-1 RA Effective for Weight Loss While Preserving BMD
THURSDAY, June 27, 2024 -- For adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective...
ADA: Tirzepatide Reduces Apnea-Hypopnea Index in Moderate-to-Severe OSA
WEDNESDAY, June 26, 2024 -- Tirzepatide reduces the apnea-hypopnea index (AHI) among individuals with moderate-to-severe obstructive sleep apnea and obesity, according to a study...
ADA: Semaglutide Similarly Effective in Men, Women With Obesity-Linked Heart Failure
WEDNESDAY, June 26, 2024 -- For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide reduces body weight to a greater extent in women...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.